Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration

Abstract Infliximab (IFX) has transformed the management of inflammatory bowel diseases (IBD). While intravenous (IV) IFX has been effective, a subcutaneous (SC) formulation offers advantages in convenience and cost. However, there is lack of evidence regarding the transition from IV to SC-IFX, espe...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Bokyeong Lee, Minjee Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Nature Portfolio 2024-10-01
Rangatū:	Scientific Reports
Ngā marau:	Infliximab Inflammatory bowel disease Subcutaneous administration Transition therapy Inadequate response
Urunga tuihono:	https://doi.org/10.1038/s41598-024-75693-7
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!